JPRN-jRCTs041190129已完成未知
A feasibility study of neoadjuvant docetaxel+cisplatin+fluorouracil (DCF) with pegfilgrastim on day3 for patients with esophageal cancer
Maeda Osamu0 个研究点目标入组 26 人开始时间: 2020年3月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 26
研究概览
简要总结
Pegfilgrastim administration on day3 was not sufficient to prevent FN due to DCF, and prophylactic administration of antibiotics was considered necessary.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •1.ECOG PS 0-1
- •2.Endoscopic biopsy of esophageal primary lesion histologically diagnosed as squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma or basal cell carcinoma.
- •3. Any of the following based on TNM classification (UICC-TNM 7 th edition)
- •1) cStage IB
- •2) cStage II
- •3) cStage III Infiltration into the trachea at the cervical /cervical chest boundary (T4) is eligible. Excluding other T4. So-called borderline-resectable T4 disease, not clearly diagnosed as T4, is eligible.
- •4) cStage IV with supraclavicular lymph node metastasis and without other distant metastasis.
- •4. Adequate organ function.
排除标准
- •1) Clear T4 other than invasion of cervical / cervical gastrointestinal tract esophageal cancer
- •2) Distant metastasis to other than supraclavicular lymph nodes.
- •3) Esophagogastric junction lesion of which main lesion is located in the stomach rather than the esophagus.
- •4) Judged not to be eligible by the researchers
研究者
相似试验
招募中
2 期
Phase II study of neoadjuvant DCF followed by adjvant S-1 for pN+ forn locally advanced esophageal cancer.Esophageal cancerJPRN-jRCTs031180375Seto Yasuyuki110
已完成
不适用
Phase II study of neoadjuvant DCF therapy followed by adjvant S-1 monotherapy for pathological lymph node metastacis cases for locally advanced esophageal cancer.Esophageal cancerJPRN-UMIN000027589The University of Tokyo98
终止
2 期
Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast CancerBreast CancerNCT00343512Vanderbilt-Ingram Cancer Center34
已完成
2 期
Validation study of FEC followed by docetaxel as preoperative chemotherapy in primary beast cancer (JBCRG-02')Primary breast cancerJPRN-C000000320Japan Breast Cancer Reaserch Group (JBCRG)20
招募中
2 期
DCF+RT for postoperative recurrent esophageal cancerJPRN-jRCTs021200009Jingu Keiichi35